For more than a year, Diane Hunter, now 72, had been experiencing vague symptoms—pain in her spine and hips, nausea, ...

Support for first and only high-risk smouldering multiple myeloma treatment came from positive phase 3 trial results ...

Multiple myeloma is a blood cancer affecting plasma cells, causing abnormal antibody production and bone damage. Diagnosis involves blood tests, bone marrow biopsy, imaging, and genetic analysis to ...

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of ...

A Stakeholder Interchange convened in Los Angeles, California, by The American Journal of Managed Care explores the treatment ...

Multiple myeloma can relapse two or more times, and tends to become more aggressive and more treatment-resistant with each ...

For the first time, patients with abnormal cells detected in their bone marrow have a treatment option before the condition ...

ASCO discussant Krina Patel, MD, of the University of Texas MD Anderson Cancer Center in Houston, noted, "Ciltacabtagene ...

Darzalex Faspro’s approval for smoldering multiple myeloma could allow for earlier intervention and reduce the risk of ...

Thermo Fisher Scientific received 510 (k) clearance from the Food and Drug Administration to market its EXENT system to aid in the diagnosis of multiple myeloma. The company's EXENT system detects and ...

The FDA approves Johnson & Johnson's Darzalex Faspro for high-risk smoldering multiple myeloma and Caplyta as an add-on ...

The FDA has approved daratumumab and hyaluronidase-fihj monotherapy as treatment for adults with high-risk smoldering ...